The Lancet. Respiratory medicine · 2026
Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Couillard Simon, Meulmeester Fleur L, Charland Pascal, Lemaire-Paquette Samuel, Howell Imran, Celis-Preciado Carlos, Lachapelle Philippe, Heaney Liam G, Bradding Peter, Mailhot-Larouche Samuel, Ramakrishnan Sanjay, Wechsler Michael E, Brusselle Guy, Diver Sarah E, Brightling Christopher E, Castro Mario, Hanania Nicola A, Jackson David J, Martin Neil, Moore Alison, Howarth Peter, Hardin Megan E, Gall Rebecca, Holweg Cecile T J, Dharman Vennila, Beasley Richard W, Sont Jacob K, Steyerberg Ewout W, Pavord Ian D, Oxford Asthma Attack Risk Scale Meta-analysis (ORACLE2) Consortium
Аннотация
BACKGROUND: Asthma symptoms often guide disease assessment and management, but their prognostic and predictive value is unclear. We evaluated the extent to which symptom burden measured by the 5-item Asthma Control Questionnaire (ACQ-5) predicts future severe asthma attacks and response to anti-inflammatory therapy.
METHODS: We conducted an individual participant data meta-analysis of selected randomised controlled trials and translational observational cohort studies of asthma of varying severity. Primary analyses used the ORACLE2 patient-level meta-analysis (n=6513) of control-group participants from 22 randomised controlled trials. Additional datasets from studies assessing type 2 targeting anti-inflammatory therapies were included on the basis of availability of data, to provide insight into the association between ACQ-5 and sputum cell counts or mediator data. Additional datasets were the DREAM intravenous mepolizumab group (n=461); a cross-sectional severe asthma cohort (SA-OT, n=74); and two acute asthma cohorts (PRISMA, biologic-naive, n=53; BOOST, anti-interleukin-5-treated, n=60). Associations between baseline ACQ-5 scores and clinical, physiological, and inflammatory profiles, asthma attack risk, and anti-inflammatory treatment responses were examined.
FINDINGS: Across five datasets encompassing 7161 distinct participants, asthma severity, lung function, inflammatory profiles, comorbidities, and ACQ-5 results varied widely. The proportion of patients with high symptom burden (ACQ-5 score >1·5) ranged from 39% to 100%. Baseline ACQ-5 showed no consistent cross-sectional association with other clinical, physiological, or inflammatory asthma features. Each 0·5-point increase in baseline ACQ-5 score was associated with a modest increase in future asthma attack risk (adjusted rate ratio [aRR] 1·09 [95% CI 1·06-1·12]; Δ R2=0·02 vs multivariable prediction model without ACQ-5). Baseline ACQ-5 score did not alter relative and absolute attack risk reduction from intravenous mepolizumab in DREAM. By contrast, patients with high blood eosinophil counts and high fractional exhaled nitric oxide (FeNO) had the highest relative and absolute risk reduction (2·81 vs 1·17 attacks; aRR 0·38 [95% CI 0·25-0·57]). In the PRISMA and BOOST datasets, ACQ-5 was not associated with post-corticosteroid lung function change. Across studies, relative and absolute treatment effects showed consistent associations with blood eosinophil counts and FeNO.
INTERPRETATION: In a large, individual patient-level meta-analysis of randomised controlled trials and translational prospective observational cohort studies, we observed little alignment of symptom burden with other clinical, physiological, or biological features of asthma and modest prognostic value for severe attacks. Conversely, type 2 biomarkers more reliably identified patients at high risk and those likely to respond to treatment. Symptoms might require contextual interpretation to guide anti-inflammatory escalation in asthma.
FUNDING: National Institute for Health and Care Research, Association Pulmonaire du Québec, Fonds de Recherche du Québec-Santé, and The Academy of Medical Sciences.
METHODS: We conducted an individual participant data meta-analysis of selected randomised controlled trials and translational observational cohort studies of asthma of varying severity. Primary analyses used the ORACLE2 patient-level meta-analysis (n=6513) of control-group participants from 22 randomised controlled trials. Additional datasets from studies assessing type 2 targeting anti-inflammatory therapies were included on the basis of availability of data, to provide insight into the association between ACQ-5 and sputum cell counts or mediator data. Additional datasets were the DREAM intravenous mepolizumab group (n=461); a cross-sectional severe asthma cohort (SA-OT, n=74); and two acute asthma cohorts (PRISMA, biologic-naive, n=53; BOOST, anti-interleukin-5-treated, n=60). Associations between baseline ACQ-5 scores and clinical, physiological, and inflammatory profiles, asthma attack risk, and anti-inflammatory treatment responses were examined.
FINDINGS: Across five datasets encompassing 7161 distinct participants, asthma severity, lung function, inflammatory profiles, comorbidities, and ACQ-5 results varied widely. The proportion of patients with high symptom burden (ACQ-5 score >1·5) ranged from 39% to 100%. Baseline ACQ-5 showed no consistent cross-sectional association with other clinical, physiological, or inflammatory asthma features. Each 0·5-point increase in baseline ACQ-5 score was associated with a modest increase in future asthma attack risk (adjusted rate ratio [aRR] 1·09 [95% CI 1·06-1·12]; Δ R2=0·02 vs multivariable prediction model without ACQ-5). Baseline ACQ-5 score did not alter relative and absolute attack risk reduction from intravenous mepolizumab in DREAM. By contrast, patients with high blood eosinophil counts and high fractional exhaled nitric oxide (FeNO) had the highest relative and absolute risk reduction (2·81 vs 1·17 attacks; aRR 0·38 [95% CI 0·25-0·57]). In the PRISMA and BOOST datasets, ACQ-5 was not associated with post-corticosteroid lung function change. Across studies, relative and absolute treatment effects showed consistent associations with blood eosinophil counts and FeNO.
INTERPRETATION: In a large, individual patient-level meta-analysis of randomised controlled trials and translational prospective observational cohort studies, we observed little alignment of symptom burden with other clinical, physiological, or biological features of asthma and modest prognostic value for severe attacks. Conversely, type 2 biomarkers more reliably identified patients at high risk and those likely to respond to treatment. Symptoms might require contextual interpretation to guide anti-inflammatory escalation in asthma.
FUNDING: National Institute for Health and Care Research, Association Pulmonaire du Québec, Fonds de Recherche du Québec-Santé, and The Academy of Medical Sciences.